texas oncology more breakthroughs. more victories
Request an Appointment

San Antonio Clinical Trials

Texas Oncology cancer centers in San Antonio participate in clinical trials and ground-breaking cancer research paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in the San Antonio area, you may be able to take part in these innovative clinical trials.

Our San Antonio cancer centers offer several types of clinical trials:

  • Prevention trials focused on preventing cancer or recurrence. For example, the trial might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
  • Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
  • Diagnostic trials determining how to identify cancers using new tests. Often, these trials involve participants who show signs or symptoms of a particular cancer.
  • Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies. They involve current cancer patients.

To review recent publications related to cancer research conducted by our physician, please click here.

Benefits and Risks of Participating in Clinical Trials

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research in the San Antonio area. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which may take more time than standard treatment.

Clinical Trial Eligibility

Your eligibility depends on several criteria, including your age and sex, your cancer type and stage of the cancer, previous treatments, and your overall medical history. If you’re interested in participating in a clinical trial, view the list of open San Antonio trials below and talk to you doctor to determine which one may be right for you.

Cancer Research Making a Difference

Advancements in cancer research are not only making headlines but also making treatment – and life – better for cancer patients. Dr. Sharon Wilks, Texas Oncology–San Antonio Northeast shares perspectives on noteworthy outcomes from breakthrough cancer research. Learn More.

Clinical Trial Principal Investigators in San Antonio

Anal Cancer

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Bladder Cancer

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-New Braunfels

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Breast Cancer

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Fredericksburg

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-New Braunfels

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA View

Description: A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT HOROMONE RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554)

Indication: Breast Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA View

Description: A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT HOROMONE RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA View

Description: A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT HOROMONE RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA View

Description: A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT HOROMONE RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph 3 BYL719 + nabpax TNBC PIK3CA View

Description: EPIK-B3: A phase III multicenter randomized double-blind placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation (CBYL719H12301)

Indication: Breast Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: Ph 3 BYL719 + nabpax TNBC PIK3CA View

Description: EPIK-B3: A phase III multicenter randomized double-blind placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation (CBYL719H12301)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: Ph 3 BYL719 + nabpax TNBC PIK3CA View

Description: EPIK-B3: A phase III multicenter randomized double-blind placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation (CBYL719H12301)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: Ph 3 BYL719 + nabpax TNBC PIK3CA View

Description: EPIK-B3: A phase III multicenter randomized double-blind placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation (CBYL719H12301)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph1a/1b LY3484356 Abem ER+ HER2- View

Description: EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (J2J-MC-JZLA)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: Ph1a/1b LY3484356 Abem ER+ HER2- View

Description: EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (J2J-MC-JZLA)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Fredericksburg

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-New Braunfels

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: IV

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph3 Nira Her2- triple- BC ctDNA (ZEST) View

Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY

Indication: Breast Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: Ph3 Nira Her2- triple- BC ctDNA (ZEST) View

Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: Ph3 Nira Her2- triple- BC ctDNA (ZEST) View

Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: Ph3 Nira Her2- triple- BC ctDNA (ZEST) View

Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph3 LY3484356 ER+ HER2- BC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigator's Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: Ph3 LY3484356 ER+ HER2- BC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigator's Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: Ph3 LY3484356 ER+ HER2- BC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigator's Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: Ph3 LY3484356 ER+ HER2- BC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigator's Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Cancer Miscellaneous

Title: A Phase III Clinical Trial for Test Use and Document Creation Only

Indication: Cancer Miscellaneous

Location: Texas Oncology-San Antonio Northeast

Phase: III

Carcinoid

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Cervical Cancer

Title: PH3 adv CC View

Description: A Randomized Phase 3 Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11)

Indication: Cervical Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Colon Cancer

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph1b Oral SM08502 CRPC CRC & NSCLC View

Description: A Phase 1b Open-Label Dose-Escalation Dose-Expansion Study Evaluating the Safety Pharmacokinetics and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Subjects with Advanced Solid Tumors (SM08502-ONC-03)

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: Ph1b Oral SM08502 CRPC CRC & NSCLC View

Description: A Phase 1b Open-Label Dose-Escalation Dose-Expansion Study Evaluating the Safety Pharmacokinetics and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Subjects with Advanced Solid Tumors (SM08502-ONC-03)

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Endometrial Cancer

Title: Ph1a/1b LY3484356 Abem ER+ HER2- View

Description: EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (J2J-MC-JZLA)

Indication: Endometrial Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: Ph1a/1b LY3484356 Abem ER+ HER2- View

Description: EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (J2J-MC-JZLA)

Indication: Endometrial Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: INCMGA00012 Endo Cancer View

Description: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204)

Indication: Endometrial Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Esophageal Cancer

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Esophageal Cancer

Location: Texas Oncology-New Braunfels

Phase: II/III

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Esophageal Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II/III

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Esophageal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II/III

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Esophageal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II/III

Fallopian Tube Cancer

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Gastric Cancer

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Gastric Cancer

Location: Texas Oncology-New Braunfels

Phase: II/III

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II/III

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II/III

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II/III

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Head and Neck Cancer

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Head and Neck Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Leukemia

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-New Braunfels

Phase: III/IV

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-San Antonio Stone Oak

Phase: III/IV

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-San Antonio Northeast

Phase: III/IV

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-San Antonio Medical Center

Phase: III/IV

Lung Cancer

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Ph 3 Sit+Nivo vs. Docetaxel NSCLC View

Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

Indication: Lung Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: Ph 3 Sit+Nivo vs. Docetaxel NSCLC View

Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: Ph 3 Sit+Nivo vs. Docetaxel NSCLC View

Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: Ph 3 Sit+Nivo vs. Docetaxel NSCLC View

Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: PH3 Nira Pembro Stg 3/4 NSCLC View

Description: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study Comparing Niraparib plus Pembrolizumab versus Placebo plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab For Stage IIIb/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)(213400)

Indication: Lung Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: PH3 Nira Pembro Stg 3/4 NSCLC View

Description: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study Comparing Niraparib plus Pembrolizumab versus Placebo plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab For Stage IIIb/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)(213400)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: PH3 Nira Pembro Stg 3/4 NSCLC View

Description: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study Comparing Niraparib plus Pembrolizumab versus Placebo plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab For Stage IIIb/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)(213400)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: PH3 Nira Pembro Stg 3/4 NSCLC View

Description: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study Comparing Niraparib plus Pembrolizumab versus Placebo plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab For Stage IIIb/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)(213400)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR Ph3 Cap OSi Peme NSCLC EGFR T90M- View

Description: A phase III randomized controlled open-label multicenter global study of capmatinib in combination with osimertinib versus platinum - pemetrexed based doublet chemotherapy in patients with locally advanced or metastatic NSCLC harboring EGFR activating mutations who have progressed on prior EGFR‑TKI therapy and whose tumors are T790M mutation negative and harbor MET amplification (GEOMETRY-E) (CINC280L12301)

Indication: Lung Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph3 Cap OSi Peme NSCLC EGFR T90M- View

Description: A phase III randomized controlled open-label multicenter global study of capmatinib in combination with osimertinib versus platinum - pemetrexed based doublet chemotherapy in patients with locally advanced or metastatic NSCLC harboring EGFR activating mutations who have progressed on prior EGFR‑TKI therapy and whose tumors are T790M mutation negative and harbor MET amplification (GEOMETRY-E) (CINC280L12301)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph3 Cap OSi Peme NSCLC EGFR T90M- View

Description: A phase III randomized controlled open-label multicenter global study of capmatinib in combination with osimertinib versus platinum - pemetrexed based doublet chemotherapy in patients with locally advanced or metastatic NSCLC harboring EGFR activating mutations who have progressed on prior EGFR‑TKI therapy and whose tumors are T790M mutation negative and harbor MET amplification (GEOMETRY-E) (CINC280L12301)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph3 Cap OSi Peme NSCLC EGFR T90M- View

Description: A phase III randomized controlled open-label multicenter global study of capmatinib in combination with osimertinib versus platinum - pemetrexed based doublet chemotherapy in patients with locally advanced or metastatic NSCLC harboring EGFR activating mutations who have progressed on prior EGFR‑TKI therapy and whose tumors are T790M mutation negative and harbor MET amplification (GEOMETRY-E) (CINC280L12301)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph1b Oral SM08502 CRPC CRC & NSCLC View

Description: A Phase 1b Open-Label Dose-Escalation Dose-Expansion Study Evaluating the Safety Pharmacokinetics and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Subjects with Advanced Solid Tumors (SM08502-ONC-03)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: Ph1b Oral SM08502 CRPC CRC & NSCLC View

Description: A Phase 1b Open-Label Dose-Escalation Dose-Expansion Study Evaluating the Safety Pharmacokinetics and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Subjects with Advanced Solid Tumors (SM08502-ONC-03)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Lymphomas

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR Ph2 A+AVD +G-CSF or AOAD in CHL View

Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Indication: Lymphomas

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Ph2 A+AVD +G-CSF or AOAD in CHL View

Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Indication: Lymphomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph2 A+AVD +G-CSF or AOAD in CHL View

Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph2 A+AVD +G-CSF or AOAD in CHL View

Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: PH3 Bren Vedo Lena Ritux r/r BC Lymph View

Description: A randomized double-blind placebo-controlled active-comparator multicenter phase 3 study of brentuximab vedotin or placebo in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)(SGN35-031)

Indication: Lymphomas

Location: Texas Oncology-New Braunfels

Phase: III

Title: PH3 Bren Vedo Lena Ritux r/r BC Lymph View

Description: A randomized double-blind placebo-controlled active-comparator multicenter phase 3 study of brentuximab vedotin or placebo in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)(SGN35-031)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: PH3 Bren Vedo Lena Ritux r/r BC Lymph View

Description: A randomized double-blind placebo-controlled active-comparator multicenter phase 3 study of brentuximab vedotin or placebo in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)(SGN35-031)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: PH3 Bren Vedo Lena Ritux r/r BC Lymph View

Description: A randomized double-blind placebo-controlled active-comparator multicenter phase 3 study of brentuximab vedotin or placebo in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)(SGN35-031)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph3 LOXO-305 vs. InvChoice in CLL/SLL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)

Indication: Lymphomas

Location: Texas Oncology-New Braunfels

Phase: III

Title: Ph3 LOXO-305 vs. InvChoice in CLL/SLL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: Ph3 LOXO-305 vs. InvChoice in CLL/SLL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: Ph3 LOXO-305 vs. InvChoice in CLL/SLL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Melanoma

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Melanoma

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Myelodysplastic Syndrome

Title: Ph 1/2 ASTX727 Lower Risk MDS View

Description: A Randomized Open-Label Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD)Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1)Myelodysplastic Syndromes (MDS) (ASTX727-03)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Ph3 Vene Aza HR-MDS View

Description: A Randomized Double-Blind Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS) (VERONA) (M15-954)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph2 IV MBG453 MDS IPSS-R View

Description: Single-arm open label phase II study of MBG453 (sabatolimab) added to FDA approved Hypomethylating agents of investigator𠏋 choice (IV/SC/Oral) for patients with intermediate high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R criteria (US multi-center) (STIMULUS MDS-US) CMBG453B1US01

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Myelofibrosis

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Ovarian Cancer

Title: PH3 Alpe BYL719 Olap BRCA OC View

Description: EPIK-O: A Phase III multi-center randomized (1:1) open-label active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy in participants with no germline BRCA mutation detected platinum-resistant or refractory high-grade serous ovarian cancer (CBYL719K12301)

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Pancreatic Cancer

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Pancreatic Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: PH2 CBP501 CIS NIVO PC WBC View

Description: CBP 21-01: Multicenter randomized parallel group phase 2 study to establish the efficacy and safety of combinations of CBP501 cisplatin and nivolumab for >/= 3rd line treatment of patients with exocrine pancreatic cancer and WBC <10000/mm3 at screening

Indication: Pancreatic Cancer

Location: Texas Oncology-New Braunfels

Phase: II

Title: PH2 CBP501 CIS NIVO PC WBC View

Description: CBP 21-01: Multicenter randomized parallel group phase 2 study to establish the efficacy and safety of combinations of CBP501 cisplatin and nivolumab for >/= 3rd line treatment of patients with exocrine pancreatic cancer and WBC <10000/mm3 at screening

Indication: Pancreatic Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: PH2 CBP501 CIS NIVO PC WBC View

Description: CBP 21-01: Multicenter randomized parallel group phase 2 study to establish the efficacy and safety of combinations of CBP501 cisplatin and nivolumab for >/= 3rd line treatment of patients with exocrine pancreatic cancer and WBC <10000/mm3 at screening

Indication: Pancreatic Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: PH2 CBP501 CIS NIVO PC WBC View

Description: CBP 21-01: Multicenter randomized parallel group phase 2 study to establish the efficacy and safety of combinations of CBP501 cisplatin and nivolumab for >/= 3rd line treatment of patients with exocrine pancreatic cancer and WBC <10000/mm3 at screening

Indication: Pancreatic Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Peritoneal Cancer

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Peritoneal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Peritoneal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Prostate Cancer

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-New Braunfels

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Stone Oak

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Northeast

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Medical Center

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph1b Oral SM08502 CRPC CRC & NSCLC View

Description: A Phase 1b Open-Label Dose-Escalation Dose-Expansion Study Evaluating the Safety Pharmacokinetics and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Subjects with Advanced Solid Tumors (SM08502-ONC-03)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: Ph1b Oral SM08502 CRPC CRC & NSCLC View

Description: A Phase 1b Open-Label Dose-Escalation Dose-Expansion Study Evaluating the Safety Pharmacokinetics and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Subjects with Advanced Solid Tumors (SM08502-ONC-03)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Renal Cancer

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Skin Cancer

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Skin Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Solid Tumors

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Ph1/2 FIH BMS-986249 + Nivo Solid Tumor View

Description: A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-New Braunfels

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Stone Oak

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-Fredericksburg

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Urothelial Cancer

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-New Braunfels

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Texas Oncology-Fredericksburg

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Fredericksburg

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Fredericksburg

Phase: IV

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-Fredericksburg

Phase: II

Texas Oncology-New Braunfels

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-New Braunfels

Phase: I/II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-New Braunfels

Title: Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA View

Description: A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT HOROMONE RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554)

Indication: Breast Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: Ph 3 BYL719 + nabpax TNBC PIK3CA View

Description: EPIK-B3: A phase III multicenter randomized double-blind placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation (CBYL719H12301)

Indication: Breast Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-New Braunfels

Phase: IV

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: Ph3 Nira Her2- triple- BC ctDNA (ZEST) View

Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY

Indication: Breast Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: Ph3 LY3484356 ER+ HER2- BC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigator's Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Esophageal Cancer

Location: Texas Oncology-New Braunfels

Phase: II/III

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Gastric Cancer

Location: Texas Oncology-New Braunfels

Phase: II/III

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-New Braunfels

Phase: III/IV

Title: Ph 3 Sit+Nivo vs. Docetaxel NSCLC View

Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

Indication: Lung Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: PH3 Nira Pembro Stg 3/4 NSCLC View

Description: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study Comparing Niraparib plus Pembrolizumab versus Placebo plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab For Stage IIIb/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)(213400)

Indication: Lung Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph3 Cap OSi Peme NSCLC EGFR T90M- View

Description: A phase III randomized controlled open-label multicenter global study of capmatinib in combination with osimertinib versus platinum - pemetrexed based doublet chemotherapy in patients with locally advanced or metastatic NSCLC harboring EGFR activating mutations who have progressed on prior EGFR‑TKI therapy and whose tumors are T790M mutation negative and harbor MET amplification (GEOMETRY-E) (CINC280L12301)

Indication: Lung Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Ph2 A+AVD +G-CSF or AOAD in CHL View

Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Indication: Lymphomas

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-New Braunfels

Phase: II

Title: PH3 Bren Vedo Lena Ritux r/r BC Lymph View

Description: A randomized double-blind placebo-controlled active-comparator multicenter phase 3 study of brentuximab vedotin or placebo in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)(SGN35-031)

Indication: Lymphomas

Location: Texas Oncology-New Braunfels

Phase: III

Title: Ph3 LOXO-305 vs. InvChoice in CLL/SLL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)

Indication: Lymphomas

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-New Braunfels

Phase: II

Title: PH2 CBP501 CIS NIVO PC WBC View

Description: CBP 21-01: Multicenter randomized parallel group phase 2 study to establish the efficacy and safety of combinations of CBP501 cisplatin and nivolumab for >/= 3rd line treatment of patients with exocrine pancreatic cancer and WBC <10000/mm3 at screening

Indication: Pancreatic Cancer

Location: Texas Oncology-New Braunfels

Phase: II

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-New Braunfels

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-New Braunfels

Phase: I/II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-New Braunfels

Phase: I/II

Texas Oncology-San Antonio Medical Center

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA View

Description: A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT HOROMONE RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph 3 BYL719 + nabpax TNBC PIK3CA View

Description: EPIK-B3: A phase III multicenter randomized double-blind placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation (CBYL719H12301)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph1a/1b LY3484356 Abem ER+ HER2- View

Description: EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (J2J-MC-JZLA)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: IV

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph3 Nira Her2- triple- BC ctDNA (ZEST) View

Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph3 LY3484356 ER+ HER2- BC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigator's Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: PH3 adv CC View

Description: A Randomized Phase 3 Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11)

Indication: Cervical Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph1b Oral SM08502 CRPC CRC & NSCLC View

Description: A Phase 1b Open-Label Dose-Escalation Dose-Expansion Study Evaluating the Safety Pharmacokinetics and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Subjects with Advanced Solid Tumors (SM08502-ONC-03)

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: Ph1a/1b LY3484356 Abem ER+ HER2- View

Description: EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (J2J-MC-JZLA)

Indication: Endometrial Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: INCMGA00012 Endo Cancer View

Description: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204)

Indication: Endometrial Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Esophageal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II/III

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II/III

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Head and Neck Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-San Antonio Medical Center

Phase: III/IV

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Ph 3 Sit+Nivo vs. Docetaxel NSCLC View

Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: PH3 Nira Pembro Stg 3/4 NSCLC View

Description: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study Comparing Niraparib plus Pembrolizumab versus Placebo plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab For Stage IIIb/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)(213400)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR Ph3 Cap OSi Peme NSCLC EGFR T90M- View

Description: A phase III randomized controlled open-label multicenter global study of capmatinib in combination with osimertinib versus platinum - pemetrexed based doublet chemotherapy in patients with locally advanced or metastatic NSCLC harboring EGFR activating mutations who have progressed on prior EGFR‑TKI therapy and whose tumors are T790M mutation negative and harbor MET amplification (GEOMETRY-E) (CINC280L12301)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph1b Oral SM08502 CRPC CRC & NSCLC View

Description: A Phase 1b Open-Label Dose-Escalation Dose-Expansion Study Evaluating the Safety Pharmacokinetics and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Subjects with Advanced Solid Tumors (SM08502-ONC-03)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR Ph2 A+AVD +G-CSF or AOAD in CHL View

Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: PH3 Bren Vedo Lena Ritux r/r BC Lymph View

Description: A randomized double-blind placebo-controlled active-comparator multicenter phase 3 study of brentuximab vedotin or placebo in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)(SGN35-031)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph3 LOXO-305 vs. InvChoice in CLL/SLL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Melanoma

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Ph 1/2 ASTX727 Lower Risk MDS View

Description: A Randomized Open-Label Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD)Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1)Myelodysplastic Syndromes (MDS) (ASTX727-03)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Ph3 Vene Aza HR-MDS View

Description: A Randomized Double-Blind Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS) (VERONA) (M15-954)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph2 IV MBG453 MDS IPSS-R View

Description: Single-arm open label phase II study of MBG453 (sabatolimab) added to FDA approved Hypomethylating agents of investigator𠏋 choice (IV/SC/Oral) for patients with intermediate high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R criteria (US multi-center) (STIMULUS MDS-US) CMBG453B1US01

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: PH3 Alpe BYL719 Olap BRCA OC View

Description: EPIK-O: A Phase III multi-center randomized (1:1) open-label active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy in participants with no germline BRCA mutation detected platinum-resistant or refractory high-grade serous ovarian cancer (CBYL719K12301)

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Pancreatic Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: PH2 CBP501 CIS NIVO PC WBC View

Description: CBP 21-01: Multicenter randomized parallel group phase 2 study to establish the efficacy and safety of combinations of CBP501 cisplatin and nivolumab for >/= 3rd line treatment of patients with exocrine pancreatic cancer and WBC <10000/mm3 at screening

Indication: Pancreatic Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Peritoneal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Peritoneal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Medical Center

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph1b Oral SM08502 CRPC CRC & NSCLC View

Description: A Phase 1b Open-Label Dose-Escalation Dose-Expansion Study Evaluating the Safety Pharmacokinetics and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Subjects with Advanced Solid Tumors (SM08502-ONC-03)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Skin Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Ph1/2 FIH BMS-986249 + Nivo Solid Tumor View

Description: A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Texas Oncology-San Antonio Northeast

Title: A Phase III Clinical Trial for Test Use and Document Creation Only

Indication: Cancer Miscellaneous

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I/II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Title: Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA View

Description: A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT HOROMONE RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: Ph 3 BYL719 + nabpax TNBC PIK3CA View

Description: EPIK-B3: A phase III multicenter randomized double-blind placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation (CBYL719H12301)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: Ph1a/1b LY3484356 Abem ER+ HER2- View

Description: EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (J2J-MC-JZLA)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: IV

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: Ph3 Nira Her2- triple- BC ctDNA (ZEST) View

Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: Ph3 LY3484356 ER+ HER2- BC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigator's Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: Ph1b Oral SM08502 CRPC CRC & NSCLC View

Description: A Phase 1b Open-Label Dose-Escalation Dose-Expansion Study Evaluating the Safety Pharmacokinetics and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Subjects with Advanced Solid Tumors (SM08502-ONC-03)

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: Ph1a/1b LY3484356 Abem ER+ HER2- View

Description: EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (J2J-MC-JZLA)

Indication: Endometrial Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Esophageal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II/III

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II/III

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-San Antonio Northeast

Phase: III/IV

Title: Ph 3 Sit+Nivo vs. Docetaxel NSCLC View

Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: PH3 Nira Pembro Stg 3/4 NSCLC View

Description: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study Comparing Niraparib plus Pembrolizumab versus Placebo plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab For Stage IIIb/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)(213400)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph3 Cap OSi Peme NSCLC EGFR T90M- View

Description: A phase III randomized controlled open-label multicenter global study of capmatinib in combination with osimertinib versus platinum - pemetrexed based doublet chemotherapy in patients with locally advanced or metastatic NSCLC harboring EGFR activating mutations who have progressed on prior EGFR‑TKI therapy and whose tumors are T790M mutation negative and harbor MET amplification (GEOMETRY-E) (CINC280L12301)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: Ph1b Oral SM08502 CRPC CRC & NSCLC View

Description: A Phase 1b Open-Label Dose-Escalation Dose-Expansion Study Evaluating the Safety Pharmacokinetics and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Subjects with Advanced Solid Tumors (SM08502-ONC-03)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph2 A+AVD +G-CSF or AOAD in CHL View

Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: PH3 Bren Vedo Lena Ritux r/r BC Lymph View

Description: A randomized double-blind placebo-controlled active-comparator multicenter phase 3 study of brentuximab vedotin or placebo in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)(SGN35-031)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: Ph3 LOXO-305 vs. InvChoice in CLL/SLL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: PH2 CBP501 CIS NIVO PC WBC View

Description: CBP 21-01: Multicenter randomized parallel group phase 2 study to establish the efficacy and safety of combinations of CBP501 cisplatin and nivolumab for >/= 3rd line treatment of patients with exocrine pancreatic cancer and WBC <10000/mm3 at screening

Indication: Pancreatic Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Northeast

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: Ph1b Oral SM08502 CRPC CRC & NSCLC View

Description: A Phase 1b Open-Label Dose-Escalation Dose-Expansion Study Evaluating the Safety Pharmacokinetics and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Subjects with Advanced Solid Tumors (SM08502-ONC-03)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: I/II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I/II

Texas Oncology-San Antonio Stone Oak

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: I/II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Title: Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA View

Description: A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT HOROMONE RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: Ph 3 BYL719 + nabpax TNBC PIK3CA View

Description: EPIK-B3: A phase III multicenter randomized double-blind placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation (CBYL719H12301)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: IV

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: Ph3 Nira Her2- triple- BC ctDNA (ZEST) View

Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: Ph3 LY3484356 ER+ HER2- BC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigator's Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Esophageal Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II/III

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II/III

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-San Antonio Stone Oak

Phase: III/IV

Title: Ph 3 Sit+Nivo vs. Docetaxel NSCLC View

Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: PH3 Nira Pembro Stg 3/4 NSCLC View

Description: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study Comparing Niraparib plus Pembrolizumab versus Placebo plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab For Stage IIIb/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)(213400)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph3 Cap OSi Peme NSCLC EGFR T90M- View

Description: A phase III randomized controlled open-label multicenter global study of capmatinib in combination with osimertinib versus platinum - pemetrexed based doublet chemotherapy in patients with locally advanced or metastatic NSCLC harboring EGFR activating mutations who have progressed on prior EGFR‑TKI therapy and whose tumors are T790M mutation negative and harbor MET amplification (GEOMETRY-E) (CINC280L12301)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph2 A+AVD +G-CSF or AOAD in CHL View

Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Indication: Lymphomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: PH3 Bren Vedo Lena Ritux r/r BC Lymph View

Description: A randomized double-blind placebo-controlled active-comparator multicenter phase 3 study of brentuximab vedotin or placebo in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)(SGN35-031)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: Ph3 LOXO-305 vs. InvChoice in CLL/SLL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: PH2 CBP501 CIS NIVO PC WBC View

Description: CBP 21-01: Multicenter randomized parallel group phase 2 study to establish the efficacy and safety of combinations of CBP501 cisplatin and nivolumab for >/= 3rd line treatment of patients with exocrine pancreatic cancer and WBC <10000/mm3 at screening

Indication: Pancreatic Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Stone Oak

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Stone Oak

Phase: I/II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: I/II

No Phase

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Fredericksburg

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-New Braunfels

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-New Braunfels

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Stone Oak

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Northeast

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase I

Title: Ph1a/1b LY3484356 Abem ER+ HER2- View

Description: EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (J2J-MC-JZLA)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: Ph1a/1b LY3484356 Abem ER+ HER2- View

Description: EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (J2J-MC-JZLA)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: Ph1b Oral SM08502 CRPC CRC & NSCLC View

Description: A Phase 1b Open-Label Dose-Escalation Dose-Expansion Study Evaluating the Safety Pharmacokinetics and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Subjects with Advanced Solid Tumors (SM08502-ONC-03)

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: Ph1b Oral SM08502 CRPC CRC & NSCLC View

Description: A Phase 1b Open-Label Dose-Escalation Dose-Expansion Study Evaluating the Safety Pharmacokinetics and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Subjects with Advanced Solid Tumors (SM08502-ONC-03)

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: Ph1a/1b LY3484356 Abem ER+ HER2- View

Description: EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (J2J-MC-JZLA)

Indication: Endometrial Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: Ph1a/1b LY3484356 Abem ER+ HER2- View

Description: EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (J2J-MC-JZLA)

Indication: Endometrial Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: Ph1b Oral SM08502 CRPC CRC & NSCLC View

Description: A Phase 1b Open-Label Dose-Escalation Dose-Expansion Study Evaluating the Safety Pharmacokinetics and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Subjects with Advanced Solid Tumors (SM08502-ONC-03)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: Ph1b Oral SM08502 CRPC CRC & NSCLC View

Description: A Phase 1b Open-Label Dose-Escalation Dose-Expansion Study Evaluating the Safety Pharmacokinetics and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Subjects with Advanced Solid Tumors (SM08502-ONC-03)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: Ph1b Oral SM08502 CRPC CRC & NSCLC View

Description: A Phase 1b Open-Label Dose-Escalation Dose-Expansion Study Evaluating the Safety Pharmacokinetics and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Subjects with Advanced Solid Tumors (SM08502-ONC-03)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: Ph1b Oral SM08502 CRPC CRC & NSCLC View

Description: A Phase 1b Open-Label Dose-Escalation Dose-Expansion Study Evaluating the Safety Pharmacokinetics and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Subjects with Advanced Solid Tumors (SM08502-ONC-03)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: Ph1/2 FIH BMS-986249 + Nivo Solid Tumor View

Description: A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Phase I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-New Braunfels

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Head and Neck Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Melanoma

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Ph 1/2 ASTX727 Lower Risk MDS View

Description: A Randomized Open-Label Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD)Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1)Myelodysplastic Syndromes (MDS) (ASTX727-03)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Pancreatic Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Skin Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-New Braunfels

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Stone Oak

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-New Braunfels

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Phase II

Title: INCMGA00012 Endo Cancer View

Description: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204)

Indication: Endometrial Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR Ph2 A+AVD +G-CSF or AOAD in CHL View

Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Indication: Lymphomas

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Ph2 A+AVD +G-CSF or AOAD in CHL View

Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Indication: Lymphomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph2 A+AVD +G-CSF or AOAD in CHL View

Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph2 A+AVD +G-CSF or AOAD in CHL View

Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: Ph2 IV MBG453 MDS IPSS-R View

Description: Single-arm open label phase II study of MBG453 (sabatolimab) added to FDA approved Hypomethylating agents of investigator𠏋 choice (IV/SC/Oral) for patients with intermediate high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R criteria (US multi-center) (STIMULUS MDS-US) CMBG453B1US01

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: PH2 CBP501 CIS NIVO PC WBC View

Description: CBP 21-01: Multicenter randomized parallel group phase 2 study to establish the efficacy and safety of combinations of CBP501 cisplatin and nivolumab for >/= 3rd line treatment of patients with exocrine pancreatic cancer and WBC <10000/mm3 at screening

Indication: Pancreatic Cancer

Location: Texas Oncology-New Braunfels

Phase: II

Title: PH2 CBP501 CIS NIVO PC WBC View

Description: CBP 21-01: Multicenter randomized parallel group phase 2 study to establish the efficacy and safety of combinations of CBP501 cisplatin and nivolumab for >/= 3rd line treatment of patients with exocrine pancreatic cancer and WBC <10000/mm3 at screening

Indication: Pancreatic Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: PH2 CBP501 CIS NIVO PC WBC View

Description: CBP 21-01: Multicenter randomized parallel group phase 2 study to establish the efficacy and safety of combinations of CBP501 cisplatin and nivolumab for >/= 3rd line treatment of patients with exocrine pancreatic cancer and WBC <10000/mm3 at screening

Indication: Pancreatic Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: PH2 CBP501 CIS NIVO PC WBC View

Description: CBP 21-01: Multicenter randomized parallel group phase 2 study to establish the efficacy and safety of combinations of CBP501 cisplatin and nivolumab for >/= 3rd line treatment of patients with exocrine pancreatic cancer and WBC <10000/mm3 at screening

Indication: Pancreatic Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Peritoneal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-Fredericksburg

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Phase II/III

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Esophageal Cancer

Location: Texas Oncology-New Braunfels

Phase: II/III

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Esophageal Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II/III

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Esophageal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II/III

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Esophageal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II/III

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Gastric Cancer

Location: Texas Oncology-New Braunfels

Phase: II/III

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II/III

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II/III

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II/III

Phase III

Title: A Phase III Clinical Trial for Test Use and Document Creation Only

Indication: Cancer Miscellaneous

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA View

Description: A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT HOROMONE RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554)

Indication: Breast Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA View

Description: A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT HOROMONE RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA View

Description: A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT HOROMONE RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA View

Description: A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT HOROMONE RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph 3 BYL719 + nabpax TNBC PIK3CA View

Description: EPIK-B3: A phase III multicenter randomized double-blind placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation (CBYL719H12301)

Indication: Breast Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: Ph 3 BYL719 + nabpax TNBC PIK3CA View

Description: EPIK-B3: A phase III multicenter randomized double-blind placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation (CBYL719H12301)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: Ph 3 BYL719 + nabpax TNBC PIK3CA View

Description: EPIK-B3: A phase III multicenter randomized double-blind placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation (CBYL719H12301)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: Ph 3 BYL719 + nabpax TNBC PIK3CA View

Description: EPIK-B3: A phase III multicenter randomized double-blind placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation (CBYL719H12301)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph3 Nira Her2- triple- BC ctDNA (ZEST) View

Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY

Indication: Breast Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: Ph3 Nira Her2- triple- BC ctDNA (ZEST) View

Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: Ph3 Nira Her2- triple- BC ctDNA (ZEST) View

Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: Ph3 Nira Her2- triple- BC ctDNA (ZEST) View

Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph3 LY3484356 ER+ HER2- BC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigator's Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: Ph3 LY3484356 ER+ HER2- BC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigator's Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: Ph3 LY3484356 ER+ HER2- BC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigator's Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: Ph3 LY3484356 ER+ HER2- BC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigator's Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: PH3 adv CC View

Description: A Randomized Phase 3 Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11)

Indication: Cervical Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph 3 Sit+Nivo vs. Docetaxel NSCLC View

Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

Indication: Lung Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: Ph 3 Sit+Nivo vs. Docetaxel NSCLC View

Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: Ph 3 Sit+Nivo vs. Docetaxel NSCLC View

Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: Ph 3 Sit+Nivo vs. Docetaxel NSCLC View

Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: PH3 Nira Pembro Stg 3/4 NSCLC View

Description: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study Comparing Niraparib plus Pembrolizumab versus Placebo plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab For Stage IIIb/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)(213400)

Indication: Lung Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: PH3 Nira Pembro Stg 3/4 NSCLC View

Description: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study Comparing Niraparib plus Pembrolizumab versus Placebo plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab For Stage IIIb/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)(213400)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: PH3 Nira Pembro Stg 3/4 NSCLC View

Description: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study Comparing Niraparib plus Pembrolizumab versus Placebo plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab For Stage IIIb/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)(213400)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: PH3 Nira Pembro Stg 3/4 NSCLC View

Description: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study Comparing Niraparib plus Pembrolizumab versus Placebo plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab For Stage IIIb/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)(213400)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR Ph3 Cap OSi Peme NSCLC EGFR T90M- View

Description: A phase III randomized controlled open-label multicenter global study of capmatinib in combination with osimertinib versus platinum - pemetrexed based doublet chemotherapy in patients with locally advanced or metastatic NSCLC harboring EGFR activating mutations who have progressed on prior EGFR‑TKI therapy and whose tumors are T790M mutation negative and harbor MET amplification (GEOMETRY-E) (CINC280L12301)

Indication: Lung Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph3 Cap OSi Peme NSCLC EGFR T90M- View

Description: A phase III randomized controlled open-label multicenter global study of capmatinib in combination with osimertinib versus platinum - pemetrexed based doublet chemotherapy in patients with locally advanced or metastatic NSCLC harboring EGFR activating mutations who have progressed on prior EGFR‑TKI therapy and whose tumors are T790M mutation negative and harbor MET amplification (GEOMETRY-E) (CINC280L12301)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph3 Cap OSi Peme NSCLC EGFR T90M- View

Description: A phase III randomized controlled open-label multicenter global study of capmatinib in combination with osimertinib versus platinum - pemetrexed based doublet chemotherapy in patients with locally advanced or metastatic NSCLC harboring EGFR activating mutations who have progressed on prior EGFR‑TKI therapy and whose tumors are T790M mutation negative and harbor MET amplification (GEOMETRY-E) (CINC280L12301)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph3 Cap OSi Peme NSCLC EGFR T90M- View

Description: A phase III randomized controlled open-label multicenter global study of capmatinib in combination with osimertinib versus platinum - pemetrexed based doublet chemotherapy in patients with locally advanced or metastatic NSCLC harboring EGFR activating mutations who have progressed on prior EGFR‑TKI therapy and whose tumors are T790M mutation negative and harbor MET amplification (GEOMETRY-E) (CINC280L12301)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: PH3 Bren Vedo Lena Ritux r/r BC Lymph View

Description: A randomized double-blind placebo-controlled active-comparator multicenter phase 3 study of brentuximab vedotin or placebo in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)(SGN35-031)

Indication: Lymphomas

Location: Texas Oncology-New Braunfels

Phase: III

Title: PH3 Bren Vedo Lena Ritux r/r BC Lymph View

Description: A randomized double-blind placebo-controlled active-comparator multicenter phase 3 study of brentuximab vedotin or placebo in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)(SGN35-031)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: PH3 Bren Vedo Lena Ritux r/r BC Lymph View

Description: A randomized double-blind placebo-controlled active-comparator multicenter phase 3 study of brentuximab vedotin or placebo in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)(SGN35-031)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: PH3 Bren Vedo Lena Ritux r/r BC Lymph View

Description: A randomized double-blind placebo-controlled active-comparator multicenter phase 3 study of brentuximab vedotin or placebo in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)(SGN35-031)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph3 LOXO-305 vs. InvChoice in CLL/SLL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)

Indication: Lymphomas

Location: Texas Oncology-New Braunfels

Phase: III

Title: Ph3 LOXO-305 vs. InvChoice in CLL/SLL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: Ph3 LOXO-305 vs. InvChoice in CLL/SLL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: Ph3 LOXO-305 vs. InvChoice in CLL/SLL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph3 Vene Aza HR-MDS View

Description: A Randomized Double-Blind Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS) (VERONA) (M15-954)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: PH3 Alpe BYL719 Olap BRCA OC View

Description: EPIK-O: A Phase III multi-center randomized (1:1) open-label active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy in participants with no germline BRCA mutation detected platinum-resistant or refractory high-grade serous ovarian cancer (CBYL719K12301)

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Peritoneal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Phase III/IV

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-New Braunfels

Phase: III/IV

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-San Antonio Stone Oak

Phase: III/IV

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-San Antonio Northeast

Phase: III/IV

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-San Antonio Medical Center

Phase: III/IV

Phase IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Fredericksburg

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-New Braunfels

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: IV